These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1723583)

  • 1. Screening for carcinoma of the prostate with prostate specific antigen.
    Muschenheim F; Omarbasha B; Kardjian PM; Mondou EN
    Ann Clin Lab Sci; 1991; 21(6):371-80. PubMed ID: 1723583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of cancer of the prostate. A study of 600 cases].
    Teillac P; Bron J; Tobolski F; Cussenot O; Lesourd A; Leroy M; Toubert ME; Brocheriou C; Laval-Jeantet M; Le Duc A
    Ann Urol (Paris); 1990; 24(1):37-41. PubMed ID: 1690963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A mass screening of the prostatic diseases and serum prostate specific antigen].
    Kato M; Okada K
    Hinyokika Kiyo; 1991 Aug; 37(8):887-90. PubMed ID: 1720276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of determining prostate-specific antigen for early detection or prostatic carcinoma].
    Hammerer P; Huland H
    Urologe A; 1995 Jul; 34(4):283-9. PubMed ID: 7545842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
    Määttänen L; Hakama M; Tammela TL; Ruutu M; Ala-Opas M; Juusela H; Martikainen P; Stenman UH; Auvinen A
    Br J Cancer; 2007 Jan; 96(1):56-60. PubMed ID: 17213825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of serum free prostate specific antigen in the screening of prostate cancer.
    Higashihara E; Nutahara K; Kojima M; Okegawa T; Miura I; Miyata A; Kato M; Sugisaki H; Tomaru T
    J Urol; 1996 Dec; 156(6):1964-8. PubMed ID: 8911366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases].
    Kato M; Okada K
    Hinyokika Kiyo; 1993 Mar; 39(3):221-3. PubMed ID: 7685140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
    Théodon P; Rymer JC; Chopin D; Kouyoudjian JC; Abbou CC; Auvert J
    Ann Urol (Paris); 1988; 22(3):199-205. PubMed ID: 2456713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
    Bangma CH; Rietbergen JB; Kranse R; Blijenberg BG; Petterson K; Schröder FH
    J Urol; 1997 Jun; 157(6):2191-6. PubMed ID: 9146612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prostate-specific antigen. A new marker of prostatic pathology].
    Boccon-Gibod L; Géraud M; Dugué MA
    Ann Urol (Paris); 1988; 22(3):206-10. PubMed ID: 2456714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of prostatic specific antigen in prostate cancer screening in the community.
    Jubelirer SJ; Tierney JP; Oliver S; Serrato JM; Farra S; Plymale J; Hodge E
    W V Med J; 1994 Apr; 90(4):140-2. PubMed ID: 7516602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advancements in PSA-based screening for prostate cancer].
    Ito K
    Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less.
    Ito K; Kubota Y; Yamamoto T; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
    Cancer; 2001 Feb; 91(4):744-51. PubMed ID: 11241242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Consensus conference. The detection of localized cancer of the prostate. Paris, 8-9 December 1989].
    Ann Urol (Paris); 1990; 24(1):5-8. PubMed ID: 1690964
    [No Abstract]   [Full Text] [Related]  

  • 17. [Serum prostate specific antigen for the early detection of prostate cancer in outpatients of internal medicine].
    Otani T; Hayashi Y; Ikuno Y; Hirao Y; Ozono S; Okajima E
    Hinyokika Kiyo; 1996 Sep; 42(9):645-9. PubMed ID: 8918662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
    J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The present role of prostatic specific antigen (PSA) as a tumor marker in carcinoma of the prostate.
    Parra RO
    Mo Med; 1991 Jun; 88(6):349-52. PubMed ID: 1712422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.